ADVFN ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Rezolute Inc

Rezolute Inc (RZLT)

4.98
0.16
(3.32%)
4.98
0.00
( 0.00% )

Calls

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.501.854.903.703.3750.000.00 %00-
5.000.100.150.150.1250.0550.00 %57811:08:03
7.500.000.100.050.050.000.00 %052-

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Puts

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.500.000.050.050.050.000.00 %010-
5.000.050.550.100.300.000.00 %029-
7.500.102.850.001.4750.000.00 %00-

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
OCCOptical Cable Corporation
$ 5.95
(64.36%)
3.16M
NDRAENDRA Life Sciences Inc
$ 4.92
(42.34%)
4.72M
LASELaser Photonics Corporation
$ 2.98
(24.69%)
1.65M
MBMasterBeef Group
$ 10.00
(13.64%)
1.15k
SYTASiyata Mobile Inc
$ 4.8285
(12.82%)
1.28M
PMAXPowell Max Ltd
$ 0.4003
(-12.98%)
299.02k
SHMDSCHMID Group NV
$ 2.98
(-12.61%)
1.71k
BTOGBit Origin Ltd
$ 0.227
(-11.33%)
17.16M
MINMMinim Inc
$ 2.93
(-9.01%)
17.99k
JWELJowell Global Ltd
$ 2.50
(-8.42%)
204
MULNMullen Automotive Inc
$ 0.252
(5.00%)
17.41M
BTOGBit Origin Ltd
$ 0.227
(-11.33%)
17.16M
CGTXCognition Therapeutics Inc
$ 0.61
(5.39%)
10.6M
HCTIHealthcare Triangle Inc
$ 0.0233
(0.87%)
9.21M
GIBOGIBO Holdings Ltd
$ 0.0694
(11.22%)
8.21M

RZLT Discussion

View Posts
Whalatane Whalatane 2 weeks ago
Three insider buys this week I think ....A $4m open market buy by a director followed by the CFO and CMO making open market purchase .

Kiwi
👍️ 1
Whalatane Whalatane 2 weeks ago
CFO buying again ...open market purchase.
https://ir.stockpr.com/rezolutebio/sec-filings-email/content/0000912282-25-000706/form4.html

I love it when CFO's make open market purchases
Kiwi
👍️ 1
Whalatane Whalatane 2 weeks ago
Thx The similarities with SLNO is that this is a rare disease market ...so will be very expensive ( but necessary ) drugs
Potential to Address Two Rare Disease Markets
• ~1,500 addressable cHI patients in US; equivalent patient population in Europe
• >500 islet cell tumor patients and >1,000 non-islet cell tumor patients addressable in the US
oHighly Concentrated Physician Base for cHI
• 60% of patients are diagnosed within 1 month of presentation
• 80% of addressable patients are seen by centers of excellence (many participating in sunRIZE study)
oTumor HI Patients Identified and treated by both Endocrinologists and Oncologists
oRegulatory Designations: Breakthrough Therapy (FDA), Orphan, Pediatric Rare Disease (FDA),
PRIME (EMA), ILAP (UK)

The drug is already being used in cell tumor patients on a compassionate use basis and has enabled these patients to leave in hospital care .
We're pretty much in a waiting game now until P 3 trial results

Re ARDX ... Mott ( chairman of the board ) is apparently still buying on the open market . I was planning to give them until mid year to work out a deal with CMS re Medicare coverage ...but so far nothings happened .
Once a position is down 20% from its recent high , or 20% below my purchase price I do a serious re evaluation and usually sell at least 50% .
With ARDX I exited completely .

I usually " sell the news "...eg FDA approval . This is because it usually takes longer and costs more than most expect , to get the new drug out into the market and break even . I sold most of my AMRN in Dec 2019 for that reason ......and more when it was down 20% from its high .

I dont plan on selling UNCY on FDA approval as I expect the drug launch will go better than most expect due to the way the new dialysis bundle works and that OLC will be distributed directly to the patients by the MD's in the dialysis clinic. No prior approval etc .

Re my " picks " . A lot of this is luck mixed in with hrs of DD and access to some MD's who treat these patients .
UNCY is likely to be under $5 or over $10 a week from now ....and I have no strong conviction on which way it's likely to break .
In fact I'm conflicted
If it's under $5 I'll be happy I can add on a sell off as I plan to hold until Q4 2026. If it's over $10 I'll be happy I've doubled my $ .
Hmmm ...looking at it that way I'll be happy either way ...
Theres something wrong with me :--)
Good luck
Kiwi
👍 2
rosemountbomber rosemountbomber 2 weeks ago
I have to echo your sentiments and also thank Kiwi for releasing some of his ideas to us. Up until a few weeks ago I also was holding on to a reduced amount of shares in ARDX but thinking that UNCY's possible success might hurt ARDX, I finally sold the remainder.

I just had a look at my retirement account and although the total value is down considerably from late 2019 (my Amarin holdings were worth money then) I feel good about what I have done there in the last 5 years. My Amarin holdings there now only make up slightly less than 18% of the total and I did that not by selling Amarin but rather by growing the remainder organically. What I mean by that is I had retired in late 2018 and no longer made any contributions to the account. Did it by buying and selling and fortunately the majority were winners and hence I grew that remainder of the portfolio.

Hopefully, we all one day are able to recoup those Amarin losses, if you are still in it.
👍️ 1
The Canes The Canes 2 weeks ago
Morning Kiwi I have RZLT. I'd asked you for a few suggestions many months ago when we were communicating on the AMRN board. You gave me three as I recall RZLT, UNCY and ARDX. I traded all three quite successfully. I know you've thrown the towel in on ARDX but I've still got a few shares. Appreciate your advice immensely!
👍️ 1
Whalatane Whalatane 2 weeks ago
From the corp presentation
BGM: blood glucose monitoring. CGM: continuous glucose monitoring.

https://ir.rezolutebio.com/corporate-presentation
Kiwi
👍️ 1
Fred Kadiddlehopper Fred Kadiddlehopper 2 weeks ago
Do you know how the study is structured to capture the data on hypoglycemic episodes among the patient population? Is it self-reporting subjective things like dizzyness and fatigue? Is it blood glucose levels from samples drawn during these events?
👍️0
Whalatane Whalatane 2 weeks ago
Fred. Vivo and Nanathala have positions in RZLT ...just not as large a % ownership as in SLNO and UNCY .
Their P 3 trial being able to continue following a DMC review , without adding more patients confirms the trial is properly powered and increases the chances of success IMHO
Add to that the roughly $4m insider buy today increases my confidence .
That being said ...it is speculative . Biotechs have a history of blowing up when you least expect them to

Kiwi
👍️ 1
rosemountbomber rosemountbomber 2 weeks ago
I know that you are not implying anything (Handoc is a partner), but my mind started racing thinking about a BO.  We will have to wait and see but the huge buy makes me feel good holding this stock. 
👍️ 1
Whalatane Whalatane 2 weeks ago

Handok Inc., along with Genexine, is a major shareholder in Rezolute, Inc., a U.S.-based biopharmaceutical company. As of January 2019, Handok and Genexine jointly held a 54% stake in Rezolute after investing $25 million. Additionally, Young-Jin Kim, Chairman and CEO of Handok and a director at Rezolute, indirectly holds 8,423,386 common shares through Handok and directly owns 149,950 shares, as reported in a $3.99 million share purchase in June 2025.
Handok also has a licensing agreement with Rezolute, signed in September 2020, granting exclusive rights to develop, import, and commercialize Rezolute’s products in South Korea.
This positions Handok as both a significant investor and a strategic partner in Rezolute’s operations.


Kiwi
👍️ 1
Whalatane Whalatane 2 weeks ago
The purchase was on behalf of a Korean pharma Co I think ...Handoc Inc

Kiwi
👍️0
Whalatane Whalatane 2 weeks ago
Huge insider buy reported today
06/13/2025 P 1,230,769 A $3.25

Thats close to a $4m open market insider buy !!

Kiwi
👍️ 1
Whalatane Whalatane 3 weeks ago
How's that working for you ?

Kiwi
👍️0
BadCuda BadCuda 4 weeks ago
https://www.marketbeat.com/stocks/NASDAQ/RZLT/short-interest/20% increase in short shares at 4.09 Gotta drop one of these days ,I'm bullish but waiting for the shorts to do their thing before I jump back in 
👍️0
Whalatane Whalatane 1 month ago
[...double post
👍️0
Whalatane Whalatane 1 month ago
Target enrollment exceeded with 62 participants enrolled, including approximately 15 percent from U.S. sites

Topline data is anticipated in December of 2025

Kiwi
👍️0
Whalatane Whalatane 2 months ago
Up 8% as I type ...the day after their presentation .
Should announce full enrollment in their pivotal trial any day now ...and set the clock for a readout out by EOY

Kiwi
👍 1
Whalatane Whalatane 2 months ago
I thought it was a good presentation . Interesting that they think the new FDA is inclined towards easier approval of rare disease indictions .
Both indications are now Breakthru designated and each represents $1B global sales potential . Breakthru gives them more access to FDA ...say thats been going well.
They still have patients on drug from the P 2 trial ...building up long term safety data .
Kiwi
👍️0
rosemountbomber rosemountbomber 2 months ago
Yep, webcast at 1:30 EDT.

https://journey.ct.events/view/cce24f5b-c8c3-49c6-bcab-cf6ab3739474
👍 1
Whalatane Whalatane 2 months ago
Their lead trial can proceed with no changes ..DMC is confident it's powered for stat sig results .
They have received Break Thru status and they successfully raised funds ,
Why would the stock fall ?
They will not develop their DME asset ...they will try and sell it

Event: H.C. Wainwright BioConnect Investor Conference
Date: May 20, 2025
There will probably be a webcast for this

Kiwi
👍️0
BadCuda BadCuda 2 months ago
23% increase in short shares April 15-30 - shorted shares = 3.48 million currently - we'll see what the may 15 report says . That should paint the picture more clearly . 
👍️0
BadCuda BadCuda 2 months ago
Technicals don't suck right now , but what information will we get before Christmas to support a 3.75 price tag . News is 6 months out and it may be bad !!! No news on DME drug - what's keeping it from falling ? 
👍️0
Whalatane Whalatane 2 months ago
Re technicals ...from my basic TA perspective ...doesnt look over bought ...or over sold .
Kiwi
👍️0
Whalatane Whalatane 2 months ago
I've been in this since

Tuesday, February 20, 2024 9:33:33 PM
Post# of 519
CFO buying http://archive.fast-edgar.com/20240220/AP27R222E222H2S2222A2CO2NABDZ222B262/


Roughly tripled since then ? I'll check the technicals but usually only pay attention to those at extremes in indicators like the RSI
Kiwi
👍️0
BadCuda BadCuda 2 months ago
The technical indicators just aren't there , like I said the company is a good company with good products - I just don't see the stock price improving until after sept . Plus the 20 million new shares handed to the same MM's that drove it down the last few times when we were news starved . Just an opinion from someone who's been watching this stock since 1.00$ 
👍️0
Whalatane Whalatane 2 months ago
Dont know why you think nothings happening with this Co

Recent Pipeline Progress and Anticipated Milestones

Congenital HI

sunRIZE, a Phase 3, multicenter, double-blind, randomized, controlled safety and efficacy registrational study, is ongoing and enrollment is expected to conclude in May 2025.
U.S. sites are activated and enrolling patients.
Topline results expected in December 2025.
Upon completion of an interim analysis in April 2025, an independent Data Monitoring Committee recommended continuation of the sunRIZE study as planned without an increase to the study sample size.
The analysis was intended to evaluate the study for futility or otherwise to inform a potential sample size increase, for purposes of optimizing the study power and statistical confidence in the final analysis outcomes.
The Company remains blinded to the results.
Tumor HI

In May 2025, FDA granted Breakthrough Therapy Designation (BTD) to ersodetug for the treatment of hypoglycemia due to tumor HI.
BTD was granted based on clinical trial data across the overall HI program and a recognition of the mechanistic applicability to tumor HI, further validated by real-world experience in tumor HI patients who have been successfully treated with ersodetug throughout the U.S. in the Company's Expanded Access Program.
A registrational study for ersodetug in patients with tumor HI, the “upLIFT” study, is anticipated to begin in the middle of 2025 with topline data expected in the second half of 2026.
Utilizing BTD, the Company plans to engage further with FDA to discuss the registrational trial, including the necessary data package to support a BLA filing and potential approval for the tumor HI indication.


Kiwi
👍️0
BadCuda BadCuda 2 months ago
Like I said I love company and it's people - MM's see what i see and will walk it down slowly until we get some news on the DME drug or ersodetug hits the market but they said it won't be finished til Xmas . Im not an expert but I've been watching/flipping this stock from 1.55 and there's a pattern MM's have of shorting , I've witnessed it several times - and the company just sold them another 21 million shares of common stock . KISS of death temporarily , more shortable shares - no real news for a few months - I would short it . First time they did this the price dropped from 5$ to 4$ overnight , second time was more of a slow walk down slowly leaking out more shares dropping the price . I was amazed it popped to 4.20 again sold it all as soon as they got those 20 million shares . I said to my self - Damm they're doing it again. So you can call it experience or luck but I seen this pony show and I held the first time but not again .when the technical signals change I'm first in lineAll in again , but the technical signals say stay away. Now  DTREF is a gold/REEMine in in Cali closed in the 90's for environmental issues when gold was340/oz . Just got more funding and federal clearance/reguest to reopen . .028 currently 2.7 billion out standing 1.7 billion float approx . Rare earth elements are getting popular so that's where I'm at now , uplisting end of may . Technical indicators are so so but it's cheap down here and moving in the right direction . 100% owned by an Australia company . 1.1 million oz of gold confirmed back in the 90's ,6 miles from the lagest gold mine in Nevada - a 4 billion dollar gold mining operation  .... hmmm .028 why not .
👍️0
Whalatane Whalatane 2 months ago
Re nothing going on this summer or fall .
They are launching their tumor trial ...now Breakthru status by FDA ,,,doubt they do anything with DME

Rezolute, Inc.
Registrational study in patients with tumor hyperinsulinism (HI) expected to commence mid-year

Designation underscores need for therapies to treat severe hypoglycemia in the oncology setting

REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by HI, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its investigational therapy, ersodetug, for the treatment of hypoglycemia caused by tumor HI.



Kiwi
👍 1
BadCuda BadCuda 2 months ago
Right , eod of year - nothing going on this summer or fall . They’ll use the new money to develope their DME drug themselves , last stage could be done by Christmas if they start now but no news on that front either . If they’re getting bought out they’ll bring the price down first before they announce anything , probably when they get closer with the DME drug and the trials are positive . Time …. It’s a great company but I just want to wait and see what their next move is - I’ll buy below 2 when we get there sorry to say , all this pr crap is for hype . Until they say there going to market and the trials went great they’re going to slowly fall in price .
👍️0
BadCuda BadCuda 2 months ago
Right , eod of year - nothing going on this summer or fall . They’ll use the new money to develope their DME drug themselves , last stage could be done by Christmas if they start now but no news on that front either . If they’re getting bought out they’ll bring the price down first before they announce anything , probably when they get closer with the DME drug and the trials are positive . Time …. It’s a great company but I just want to wait and see what their next move is - I’ll buy below 2 when we get there sorry to say , all this pr crap is for hype . Until they say there going to market and the trials went great they’re going to slowly fall in price .
👍️0
Whalatane Whalatane 2 months ago
FWIW. HC Wainwright & Co. Reiterates Buy on Rezolute, Maintains $14 Price Target
BENZINGA - 1:41 PM ET 4/28/2025


Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism, today announced that management will participate in the following investor conferences:
Event: The Citizens JMP Life Sciences Conference
Date: May 7-8, 2025

Event: H.C. Wainwright BioConnect Investor Conference
Date: May 20, 2025

Event: Craig-Hallum Institutional Investor Conference
Date: May 28, 2025

Event: Jefferies Global Healthcare Conference
Date: June 3-5, 2025

Management will be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their JMP, H.C. Wainwright, Craig-Hallum, and Jefferies representatives.

Meeting one on one with investors ...otherwise known as checking out any buy out interest .
Unlikely this Co launch their drug alone , once approved
JMO

Kiwi
👍️0
BadCuda BadCuda 2 months ago
20 mil new shares at 3.25 , my guess is they short it to get below 3.25 to grab a bunch more from sellers as it keeps going down - watch for short report  . No life changing news for stock right now , trials continue lets see how long they drag out the selling . Watching technicals for reentry . This is all Just my opinion 
👍️0
Monksdream Monksdream 2 months ago
RZLT, recent 52 week low
👍️0
rosemountbomber rosemountbomber 2 months ago
In Caribbean and not all are sea days. I couldn’t find the spreadsheet North alluded to in terms of BOs. I guess it depends when you take. The start point for BO to figure out multiple
👍️0
Whalatane Whalatane 2 months ago
They will need the $ for the Tumor HI P 3 trial thats about to ramp up.
Drug is currently in use at major research hospitals like Stanford
Rezolute’s EAP has demonstrated success in individual cases, particularly for tumor-mediated hyperinsulinism, leading to FDA clearance for a Phase 3 study in this indication. Patients in the EAP have experienced significant benefits, such as hospital discharge and resumed cancer therapy, highlighting the program’s role in addressing critical unmet needs.

The program operates under FDA’s expanded access framework, often called “compassionate use,” which allows access to investigational drugs like RZ358 (ersodetug), a monoclonal antibody that modulates insulin receptor activity to manage hypoglycemia.

Addressing critical unmet needs means fast tracked and high price for the drug on approval

Kiwi
👍️0
BadCuda BadCuda 2 months ago
Looks like they got 90 mill to do their own trials for their DME product , just a hiesss because they didn't need it for the HI drug - they just waiting on results and by the options play calling for 2.50 . I'm gonna wait and see - these small caps can drop in a day but by Christmas we should have some better idea what's going on .
👍️0
Whalatane Whalatane 2 months ago
Re no news in sight . You're forgetting about the drug in trial for Tumor HI
IND filed and cleared: start-up activities in progress to enable patient enrollment in 1H 2025
The drug is already in use ( compassionate use ) at some major hospitals like Stanford , for Tumor HI

Kiwi
👍️0
Whalatane Whalatane 2 months ago
Staying in cash til we get below 3 . Bold call .
Guess you dont think this is a buyout candidate for anyone .
Re no news in sight . They will announce full enrollment in their pivotal trial next mth so then its count down to read out .
Drug is fast tracked ....so data by EOY
Kiwi
👍️0
Whalatane Whalatane 2 months ago
Couple of weeks at sea ? Where are U going ?
Kiwi
👍️0
BadCuda BadCuda 2 months ago
20 million new shares ( bought at 3.25) hitting the market with no real news in sight , gotta see the q report . IMO they're going to short this down to 2.50 area . Gap to fill as well back to 3.1-3.5  Staying in cash til we get below 3. Good luck
👍️0
rosemountbomber rosemountbomber 2 months ago
Thanks. Yes and I will remain on those seas for another couple of weeks. As you can see I get the odd opportunity to post and was glad to catch the announcement of this trial’s DMC. Analysts’ targets on this are mid teens.
👍️0
Whalatane Whalatane 2 months ago
Co's almost always raise $ within a day or two of positive data ...strike while the iron is hot etc . Yes ...implies no interest in their DME drug.
Groks take on the data


The interim analysis of Rezolute, Inc.'s (RZLT) Phase 3 sunRIZE study for ersodetug in congenital hyperinsulinism (HI), announced on April 23, 2025, provides significant insights into the trial's progress. Below is an evaluation based on available information, focusing on the implications of the Data Monitoring Committee's (DMC) recommendation and the trial's context.

Key Points from the Interim Analysis
DMC Recommendation:
The independent DMC reviewed unblinded interim data after approximately half of the enrolled patients completed primary assessments, focusing on hypoglycemia events as the primary endpoint.

The DMC recommended continuing the trial as planned without increasing the sample size. This suggests that the observed effect size and variability align with the statistical assumptions used in the original trial design, indicating the study is likely adequately powered to detect the pre-specified treatment effect.

Trial Status and Timeline:
Enrollment is on track to be completed by May 2025, with topline data expected in December 2025.

U.S. clinical sites are actively enrolling patients, expanding the global study’s reach.

Rezolute remains blinded to the interim data and statistical outputs, maintaining trial integrity.

Supporting Evidence:
The DMC’s recommendation aligns with prior Phase 2 RIZE study outcomes, real-world observations from Rezolute’s Expanded Access Program, and pharmacokinetic data from the sunRIZE study’s open-label arm. This consistency strengthens confidence in ersodetug’s potential efficacy.

Market and Sentiment Impact:
Posts on X reflect positive sentiment, with users noting the DMC’s recommendation as a procedural milestone and viewing the stock as undervalued, especially after a recent capital raise. However, some expressed mild concern about the timing of the raise diluting shares.

The announcement was seen as de-risking the trial, as no sample size adjustment was needed, reinforcing investor confidence.

Implications for Statistical Power and Trial Success
Adequate Powering: The DMC’s decision not to increase the sample size strongly suggests that the interim data showed an effect size and variability consistent with the trial’s design. In clinical trials, interim analyses assess whether the study remains on track to detect a statistically significant effect with the planned sample size. The lack of a sample size adjustment implies the trial is likely sufficiently powered, assuming no major deviations in the remaining data.

Efficacy Signals: While specific interim results (e.g., p-values or effect sizes) were not disclosed to maintain blinding, the DMC’s endorsement without modifications indirectly supports the hypothesis that ersodetug is performing as expected, especially given alignment with Phase 2 and real-world data.

Risk of Futility or Harm: The DMC did not recommend stopping for futility or safety concerns, which is a positive signal. In trials, DMCs may halt studies early if the treatment shows no chance of achieving significance (futility) or poses safety risks. The absence of such recommendations reduces these risks.

Potential Risks and Considerations
Interim Data Limitations: Interim analyses are based on partial data, and results can change as more patients are enrolled. For example, literature notes that interim results may overestimate treatment effects compared to final outcomes, and premature conclusions should be avoided.

Statistical Risks: Multiple interim analyses increase the risk of type I errors (false positives) unless adjusted for, though the sunRIZE study’s protocol likely includes methods like O’Brien-Fleming or Pocock to control this. The announcement did not specify the statistical approach, but adherence to rigorous standards is assumed.

Market Expectations: Positive sentiment on X could inflate expectations, but topline data in December 2025 will be the true test. If final results underperform interim signals, stock volatility could follow.

Rare Disease Context: Congenital HI is a rare condition, which may limit patient recruitment and generalizability. However, active U.S. site enrollment mitigates some recruitment concerns.

Comparison to Broader Clinical Trial Context
Similar Trials: In contrast to the HOVON 132 trial, where Bayesian interim analyses signaled futility early but the trial continued to a negative final outcome, RZLT’s DMC recommendation suggests a more promising trajectory.

Adaptive Designs: The sunRIZE study appears to follow a group-sequential design, common in Phase 3 trials, allowing interim checks without compromising statistical integrity. The lack of sample size adjustment contrasts with trials requiring increases due to lower-than-expected effect sizes.

Conclusion
The interim analysis of RZLT’s Phase 3 sunRIZE study is a positive milestone, as the DMC’s recommendation to continue without increasing the sample size indicates the trial is likely adequately powered and on track to detect a statistically significant effect on hypoglycemia events. Consistency with Phase 2 and real-world data further supports ersodetug’s potential efficacy, and the absence of futility or safety concerns reduces key risks. However, interim results are not definitive, and final topline data in December 2025 will determine success. Investors and stakeholders should remain cautiously optimistic, mindful of statistical risks and the rare disease context. For further details, refer to Rezolute’s official announcements or clinical trial registries.


I'm really impressed with the Grok AI
U still on the high seas ?
Kiwi
👍️0
rosemountbomber rosemountbomber 2 months ago
Any thought Kiwi as to whether they could have waited a bit to raise cash? I would think the good news about the trial would imply a rising stock price. On the other hand they must not be able to sell their other drug.
👍️0
Whalatane Whalatane 2 months ago
Without real news !!!! Geez they didn't have to add any more patients to the trial. DMC has determined the trial is properly powered to provide a stat sig result .
Thats fantastic news ...and they raised $ into that and the stock still went up .
Kiwi
👍️ 1
BadCuda BadCuda 2 months ago
Crazy volume without real news scares me , .92 pop today and 20 million shares added to the float I feel a short coming soon-  maybe they'll release the q report first so we pop to 5 . Sold off trading shares at 4 today off my 2.70 buys . Buy back at 3.50 area maybe with Big gap to fill there 
👍️0
Whalatane Whalatane 2 months ago
Yep , no need to increase enrollment , fully enrolled next mth , data by EOY ...they also did a capital raise
Kiwi
👍️0
glenn1919 glenn1919 2 months ago
RZLT.............................................................................https://stockcharts.com/h-sc/ui?s=RZLT&p=W&b=5&g=0&id=p86431144783
👍️0
rosemountbomber rosemountbomber 2 months ago
Well they announce positive rec today. I am at sea so can’t monitor much:
https://stocks.apple.com/AzJxVr1fqRJKr2h6Cm7TMrw
👍️ 1
Whalatane Whalatane 3 months ago
Well price action ( up 16% as I type ) ...hopefully indicates the interim data due any day ...is positive
Kiwi
👍️0
Whalatane Whalatane 3 months ago
Well theres a certain risk off ....on anything speculative ...thats tracking the general market .
Compare the movement today with the changes in the S&P .
IMHO it's very unlikely the trial gets stopped for futility ....probably 50% chance they need / or want ...to add more patients to increase the statistical power .
CEO , CFO and a board member have all been making open market buys ....so they must feel pretty confident on eventually getting a drug approved.

UNCY is green even tho Dow is down over 1,000 pts ...!

Kiwi
👍️0

Your Recent History

Delayed Upgrade Clock